OPKO Health
OPK Small CapHealthcare · Diagnostics & Research
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
OPKO Health en bref
OPKO Health (OPK) is currently trading at 1,24 € with a market capitalization of 935 M €. The 52-week range spans from 0,85 € to 1,39 €; the current price is 11.3% below the yearly high. Year-over-year revenue growth stands at -17.2%.
💰 Dividende
OPKO Health currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
5 analystes évaluent OPKO Health (OPK) au consensus : Acheter. L'objectif de cours moyen est de 3,28 €, soit un potentiel de +164.79% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 1,13 € à 7,41 €.
OPKO Health : la thèse d'investissement en détail
OPKO Health (OPK) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Wall Street consensus sits at Buy with an average price target implying roughly 164.79% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Revenue is contracting at -17.2% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.
Valorisation en contexte
At a PEG of 93.65, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.
À surveiller
- The analyst consensus price target implies 164.79% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Consensus des analystes : Buy
- Bilan solide avec faible endettement (D/E 32.95)
- –CA en contraction (-17.2% sur un an)
- –Actuellement non rentable
- –Free cash flow négatif
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to market-like volatility, elevated short interest (7.8%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy OPKO Health?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
